Details for Patent: 7,442,830
✉ Email this page to a colleague
Which drugs does patent 7,442,830 protect, and when does it expire?
Patent 7,442,830 protects NINLARO and is included in one NDA.
This patent has sixty patent family members in thirty-six countries.
Summary for Patent: 7,442,830
| Title: | Proteasome inhibitors |
| Abstract: | The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
| Inventor(s): | Olhava; Edward J. (Cambridge, MA), Danca; Mihaela Diana (Mendham, NJ) |
| Assignee: | Millenium Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 11/890,412 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,442,830 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
More… ↓ |
Drugs Protected by US Patent 7,442,830
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||
| Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,442,830
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2178888 | ⤷ Subscribe | PA2017010 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | 300871 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | 122017000025 | Germany | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | CA 2017 00014 | Denmark | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | C20170014 00227 | Estonia | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | PA2017010,C2178888 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2178888 | ⤷ Subscribe | LUC00013 | Luxembourg | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
